Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic

Katherine L Thayer1, Elric Zweck1,2, Mohyee Ayouty3

  • 1The CardioVascular Center, Tufts Medical Center, Boston, MA (K.L.T., E.Z., K.J.M., S.N., J.L.H., N.M.H., M.L.E., C.D.D., J.U., N.K.K.).

Circulation. Heart Failure
|September 9, 2020
PubMed

Insights

The Society for Cardiovascular Angiography and Interventions (SCAI) stages effectively risk-stratify patients with cardiogenic shock (CS), identifying those at higher risk for in-hospital mortality. Venous congestion is also a key indicator of mortality risk in CS patients.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Health Outcomes Research

Background:

  • Risk stratification for cardiogenic shock (CS) is a critical unmet need.
  • The Society for Cardiovascular Angiography and Interventions (SCAI) staging system is a proposed tool for identifying CS patients at risk of in-hospital mortality.
  • The utility of SCAI stages and the impact of hemodynamic congestion on CS outcomes require further investigation.

Purpose of the Study:

  • To evaluate the utility of the SCAI staging system in risk stratifying patients with cardiogenic shock.
  • To explore the impact of hemodynamic congestion on clinical outcomes in patients with CS.
  • To assess the association between SCAI stages, hemodynamic congestion, and in-hospital mortality.

Main Methods:

  • Utilized the CS Working Group registry, including 1414 patients from 8 medical centers (2016-2019).
  • Classified patients by maximum SCAI stage (B-E) based on treatment utilization.
  • Analyzed in-hospital mortality in relation to SCAI stages and hemodynamic congestion parameters.

Main Results:

  • In-hospital mortality was 31% overall, higher in myocardial infarction (MI) CS (41%) than heart failure (HF) CS (26%).
  • Increasing SCAI stage was significantly associated with higher in-hospital mortality (OR, 3.25 [95% CI, 2.63-4.02]).
  • Elevated right atrial pressure, indicating venous congestion, was linked to increased mortality and higher SCAI stages.

Conclusions:

  • The SCAI staging system is associated with in-hospital mortality in patients with CS due to HF and MI.
  • Venous congestion is prevalent in CS and independently identifies patients at high risk for mortality.
  • Findings support the use of SCAI staging and monitoring venous congestion for improved CS management and clinical trial design.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
187
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
493
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
165
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
555
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.3K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
326